DWM
GMAB icon

Diversify Wealth Management’s Genmab GMAB Stock Holding History

Diversify Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,564
Closed -$1.22M – 1309
2026
Q1 		$1.22M Buy
+46,564
New +$1.4M 0.02% 536

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Diversify Wealth Management's GMAB Position: Q2 2026 in Review

Diversify Wealth Management sold out of Genmab (GMAB) in Q2 2026, closing a stake of 46,564 shares — an estimated $1.22M sold.

Diversify Wealth Management first reported a position in GMAB in Q1 2026 and held it in 1 quarter. The position peaked at $1.22M in Q1 2026. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Diversify Wealth Management reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Diversify Wealth Management sold 46,564 Genmab shares in Q2 2026, an estimated $1.22M.
  • Diversify Wealth Management first reported a position in Genmab in Q1 2026 and held it in 1 quarter.
  • Diversify Wealth Management's Genmab position peaked at $1.22M in Q1 2026.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Diversify Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.